Track topics on Twitter Track topics that are important to you
320 Putman Av.
United States of America
Phone: 1 617 868 3797
Fax: 1 617 868 0109
MADRID, July 27, 2018 /PRNewswire/ -- PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum...
(Pharmamar) On April 27th, 2018 PharmaMar (MSE:PHM) reported to National Securities Market Commission that Chugai Pharmaceutical Co., Ltd. had exercised its right to terminate without cause the Licens...
(Pharmamar) Both institutions will combine their efforts, knowledge and resources to promote research into marine biodiversity as a source of novel antitumor compounds.
The FDA granted orphan drug status to PharmaMar's PM1183, or lurbinectedin, which is being developed as a treatment for patie -More-
(Pharmamar) PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after...
PharmaMar announces that the Australian Regulatory Agency (TGA) has informed STA that Aplidin (plitidepsin) has been approved for the treatment of multiple myeloma in combination with dexamethasone.
MADRID, June 11, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the ma...
PharmaMar (MCE: PHM) announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer. The FDA’s Office of Orphan Drug Products grants orph...
PharmaMar was founded in 1986, as part of the Zeltia group, with the vision of exploiting the great potential of the oceans as a source of novel medicines for improved cancer treatment. PharmaMar head...
PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is Spain's first anti-cancer drug. It ...
Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of ...
Instituto de Inmunología y Alergia, S.A. (INMUNAL, S.A.) es una compañía que viene desarrollando su actividad desde 1.989, en el estudio y elaboración de productos inmunológicos personalizados di...
We have published hundreds of PharmaMar USA news stories on BioPortfolio along with dozens of PharmaMar USA Clinical Trials and PubMed Articles about PharmaMar USA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PharmaMar USA Companies in our database. You can also find out about relevant PharmaMar USA Drugs and Medications on this site too.
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...